血清AMH、INHB、TGF-β1水平联合检测对卵巢早衰的诊断价值分析

doi:10.3760/cma.j.cn441417-20241011-06023

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (6): 996-1000.DOI: 10.3760/cma.j.cn441417-20241011-06023

血清AMH、INHB、TGF-β1水平联合检测对卵巢早衰的诊断价值分析

田波史冬冬申延兴

濮阳油田总医院医学检验科，濮阳 457001

收稿日期:2024-10-11 出版日期:2025-03-15 发布日期:2025-03-17
通讯作者: 田波，Email：tian1015TT@163.com
基金资助:
河南省医学科技攻关联合共建项目（LHGJ20221084）

Value of combined detection of serum AMH, INHB, and TGF-β1 levels in diagnosis of premature ovarian failure

Tian Bo, Shi Dongdong, Shen Yanxing

Department of Medical Laboratory, Puyang Oilfield General Hospital, Puyang 457001, China

Received:2024-10-11 Online:2025-03-15 Published:2025-03-17
Contact: Tian Bo, Email: tian1015TT@163.com
Supported by:
Problem-tackling Co-construction Project of Medical Science and Technology in Henan (LHGJ20221084)

摘要/Abstract

摘要：

目的　探究血清抗苗勒管激素（AMH）、抑制素B（INHB）、转化生长因子β受体1（TGF-β1）水平联合检测对卵巢早衰的诊断价值。方法　采用回顾性研究，选取濮阳油田总医院2023年3月至2024年3月收治的105例卵巢早衰患者为观察组，另选取同期月经周期正常的健康体检女性105名为对照组。观察组：年龄25～39（32.15±2.78）岁，体重指数19.9～26.8（23.24±1.62）kg/m²；对照组：年龄24～38（31.51±3.04）岁，体重指数19.7～26.9（22.96±1.58）kg/m²。对比两组血清AMH、INHB、TGF-β1水平，分析血清AMH、INHB、TGF-β1水平与卵巢早衰发生的相关性与危险度，以及对卵巢早衰的诊断价值。统计学方法采用t检验。结果　观察组血清AMH、INHB、TGF-β1水平均低于对照组［（2.51±0.62）μg/L比（13.74±3.45）μg/L、（41.12±10.58）ng/L比（106.24±30.62）ng/L、（151.54±15.27）ng/L比（285.44±34.38）ng/L］，差异均有统计学意义（t=-32.829、-20.597、-36.473，均P<0.05）。血清AMH、INHB、TGF-β1水平均与卵巢早衰发生呈负相关（r=-0.648、-0.623、-0.659，均P<0.05）。血清AMH（OR=7.306，95%CI 5.983～8.921）、INHB（OR=7.680，95%CI 6.387～9.234）、TGF-β1（OR=8.762，95%CI 7.245～10.597）水平均是患者发生卵巢早衰的独立影响因素（均P<0.05）。血清AMH、INHB、TGF-β1水平及联合检测诊断卵巢早衰发生的曲线下面积（AUC）分别为0.631、0.619、0.702、0.849（均P<0.05）；血清AMH、INHB、TGF-β1高水平者发生卵巢早衰分别是低水平的0.470倍、0.530倍、0.391倍（均P<0.05）。结论　血清AMH、INHB、TGF-β1水平与卵巢早衰发生关系密切，各指标联合检测可为临床诊断卵巢早衰提供参考。

关键词:

卵巢早衰, 抗苗勒管激素, 抑制素B, 转化生长因子β受体1

Abstract:

Objective　To explore the value of combined detection of serum anti-Müllerian hormone (AMH), inhibin B (INHB), and transforming growth factor beta receptor 1 (TGF-β1) levels in the diagnosis of premature ovarian failure. Methods　A total of 105 patients with premature ovarian failure treated at Puyang Oilfield General Hospital from March 2023 to March 2024 were selected as an observation group; 105 healthy female examinees with normal menstrual cycles in the same period were selected as a control group. The observation group were 25-39 (32.15±2.78) years old; their body mass index was 19.9-26.8 (23.24±1.62) kg/m². The control group were 24-38 (31.51±3.04) years old; their body mass index was 19.7-26.9 (22.96±1.58) kg/m². The serum levels of AMH, INHB and TGF-β1 were compared between the two groups. The correlation of the serum levels of AMH, INHB and TGF-β1 with the occurrence of premature ovarian failure was analyzed. The risk of premature ovarian failure was analyzed. The diagnostic value of serum levels of AMH, INHB and TGF-β1 for premature ovarian failure was analyzed. t test was used for the statistical analysis. Results　The levels of serum AMH, INHB, and TGF-β1 in the observation group were lower than those in the control group [(2.51±0.62) μg/L vs. (13.74±3.45) μg/L, (41.12±10.58) ng/L vs. (106.24±30.62) ng/L, and (151.54±15.27) ng/L vs. (285.44±34.38) ng/L; t=-32.829, -20.597, and -36.473; all P<0.05]; the levels of serum AMH, INHB, and TGF-β1 were negatively correlated with the occurrence of premature ovarian failure (r=-0.648, -0.623, and -0.659; all P<0.05); the levels of serum AMH (OR=7.306,95%CI 5.983-8.921), INHB(OR=7.680,95%CI 6.387-9.234), and TGF-β1 (OR=8.762,95%CI 7.245-10.597) were independent influencing factors for the occurrence of premature ovarian failure in the patients ( all P<0.05). The areas under the curves (AUC) of AMH, INHB, TGF-β1, and their combination in the diagnosis of premature ovarian failure were 0.631, 0.619, 0.702, and 0.849, respectively (P<0.05). The individuals with high serum levels of AMH, INHB, and TGF-β1 were 0.470, 0.530, and 0.391 times more likely to experience premature ovarian failure compared to those with low levels (all P<0.05). Conclusion　The serum levels of AMH, INHB, and TGF-β1 are closely related to the occurrence of premature ovarian failure, and the combined detection of these indicators can provide references for the clinical diagnosis of premature ovarian failure.

Key words:

Premature ovarian failure, Anti-Müllerian hormone, Inhibin B, Transforming growth factor beta receptor 1

田波史冬冬申延兴.

血清AMH、INHB、TGF-β1水平联合检测对卵巢早衰的诊断价值分析 [J]. 国际医药卫生导报, 2025, 31(6): 996-1000.

Tian Bo, Shi Dongdong, Shen Yanxing.

Value of combined detection of serum AMH, INHB, and TGF-β1 levels in diagnosis of premature ovarian failure [J]. International Medicine and Health Guidance News, 2025, 31(6): 996-1000.

参考文献

[1] 张媛媛,黑江荣,袁秀红,等. 经皮雌激素对卵巢早衰患者血清性激素、超敏C反应蛋白、血脂及凝血功能的影响[J]. 中国妇产科临床杂志,2021,22(1):64-65. DOI:10.13390/j.issn.1672-1861.2021.01.023.
[2] Aboutalebi H, Alipour F, Ebrahimzadeh-Bideskan A. The protective effect of co-administration of platelet-rich plasma (PRP) and pentoxifylline (PTX) on cyclophosphamide-induced premature ovarian failure in mature and immature rats[J]. Toxicol Mech Methods, 2022,32(8):588-596.DOI: 10.1080/15376516.2022. 2057264.
[3] 刘萍,黄健,谢宝国. 血红素加氧酶-1基因转染骨髓间充质干细胞移植对化疗所致卵巢早衰的保护作用[J]. 中国临床药理学杂志,2023,39(5):679-683. DOI:10.13699/j.cnki.1001-6821.2023.05.015.
[4] 孙娜,高树苓,安朗,等. 卵巢早衰患者血清抑制素B、抗苗勒管激素及性激素水平与子宫动脉血流参数的相关性研究[J]. 现代生物医学进展,2021,21(5):992-995. DOI:10.13241/j.cnki.pmb.2021.05.041.
[5] Zheng S, Ma M, Chen Y, et al. Effects of quercetin on ovarian function and regulation of the ovarian PI3K/Akt/FoxO3a signalling pathway and oxidative stress in a rat model of cyclophosphamide-induced premature ovarian failure[J]. Basic Clin Pharmacol Toxicol, 2022,130(2):240-253.DOI: 10.1111/bcpt.13696.
[6] 中国中西医结合学会妇产科专业委员会. 早发性卵巢功能不全中西医结合诊疗指南[J]. 中医杂志,2022,63(12):1193-1198. DOI:10.13288/j.11-2166/r.2022.12.017.
[7] Lotz L, Dietl A, Hoffmann I,et al. Endometriosis in women undergoing ovarian tissue transplantation due to premature menopause after gonadotoxic treatment or spontaneous premature ovarian failure[J]. Acta Obstet Gynecol Scand,2022 ,101(7):771-778.DOI: 10.1111/aogs.14374.
[8] 胡菊,任涛涛,何文艳. 激素替代疗法联合左归丸加减治疗肾阴虚卵巢早衰的临床效果研究[J]. 海南医学,2023,34(21):3069-3073. DOI:10.3969/j.issn.1003-6350.2023. 21.006.
[9] 何凤屏,刘彦慧,熊符,等. miR-146调控TLR4/NF-κB通路减少卵泡颗粒细胞凋亡及干预卵巢早衰中的机制研究[J]. 现代检验医学杂志,2023,38(1):77-82. DOI:10.3969/j.issn.1671-7414.2023.01.015.
[10] 吴洁,刘彦礼,秦艺璐,等. 骨髓间充质干细胞来源外泌体的微小RNA-22-3p参与抑制环磷酰胺诱导卵巢颗粒细胞损伤的机制研究[J]. 实用临床医药杂志,2024,28(4):39-44. DOI:10.7619/jcmp.20233603.
[11] 张琼,卢文波,虞可文,等. 血清抗米勒管激素诊断早发性卵巢功能不全和卵巢早衰患者价值研究[J]. 中国实用妇科与产科杂志,2023,39(1):98-101. DOI:10.19538/j.fk2023010122.
[12] 武明莉,娄欢,刘芳.卵巢早衰患者血清IL-21、AMH水平变化及其诊断价值[J].中国计划生育学杂志,2020,28(6):847-849.
[13] 王龙影,许文强,顾丽霞,等. 不同病程自身免疫性卵巢早衰患者血清BMP15、1L-1β、INHB、MIF的变化及与性激素和T淋巴细胞亚群的相关性研究[J]. 现代生物医学进展,2022,22(18):3568-3572. DOI:10.13241/j.cnki.pmb.2022.18.032.
[14] 吴金霞,聂淑玲,赵蓉,等. 血清INHB、AMH、FSH及LH水平预测卵巢储备功能下降价值及促排卵治疗后腔内超声评估[J]. 中国计划生育学杂志,2022,30(4):836-840. DOI:10.3969/j.issn.1004-8189.2022.04.024.
[15] Ebid AHIM, Abdel Motaleb SM, Mostafa MI,et al. Population PK-PD-PD modeling of recombinant follicle stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection: implications on dosing and timing of gonadotrophin therapy[J]. J clin pharmacol,2021,61(5):700-713.DOI: 10.1002/jcph.1792.
[16] 张于念,田海清,腊晓琳. 免疫性卵巢早衰小鼠外周血CD4+CD25+Treg细胞及其相关因子变化与Tim-3的关系[J]. 山东医药,2020,60(2):35-38. DOI:10.3969/j.issn. 1002-266X.2020.02.009.
[17] 杨贤慧,方霞,刘爱胜,等. 卵巢早衰患者血清TNF-α、TGF-β1水平及TNF-α基因308G/A位点多态性分析[J]. 现代免疫学,2021,41(3):220-223.
[18] Cao Y, Chen Y, Wang P,et al. Network pharmacology and experimental validation to explore the molecular mechanisms of Bushen Huoxue for the treatment of premature ovarian insufficiency[J]. Bioengineered, 2021,12(2):10345-10362. DOI: 10.1080/21655979. 2021.1996317.

血清AMH、INHB、TGF-β1水平联合检测对卵巢早衰的诊断价值分析

Value of combined detection of serum AMH, INHB, and TGF-β1 levels in diagnosis of premature ovarian failure

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics